-

09:15:20 AM

CEMI Stock News

CEMI - Chembio Diagnostics Inc.

03/21/23 7:00 AM

Nasdaq : CEMI

Chembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. Fellow Chembio

RHEA-AI

neutral

03/15/23 7:00 AM

Nasdaq : CEMI

Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. (“Purchaser”), a Nevada corporation and its wholly-owned indirect

RHEA-AI

neutral

03/15/23 7:00 AM

Nasdaq : CEMI

Chembio Announces Letter to Stockholders Regarding Tender Offer

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. March 15, 2023 Fellow

RHEA-AI

neutral

02/24/23 8:00 AM

Nasdaq : CEMI

Chembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis System

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced receipt of a Clinical Laboratory Improvement Amendments (CLIA) waiver from the U.S. Food and Drug Administration

RHEA-AI

neutral

01/31/23 5:00 PM

Nasdaq : CEMI

acquisition

Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement

RHEA-AI

positive

11/28/22 8:00 AM

Nasdaq : CEMI

Chembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis System

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission to the U.S. Food and Drug Administration (FDA) for a Clinical Laboratory Improvement Amendments

RHEA-AI

neutral

11/03/22 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports Third Quarter 2022 Financial Results

Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights

RHEA-AI

neutral

10/20/22 4:05 PM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday,

RHEA-AI

neutral

09/06/22 8:00 AM

Nasdaq : CEMI

Chembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm Assay

Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it was awarded a $3.2 million contract from the Centers for Disease Control and Prevention (CDC) for

RHEA-AI

neutral

08/16/22 8:00 AM

Nasdaq : CEMI

Chembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test Development

Chembio Diagnostics, Inc. (Chembio) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced it is evaluating the potential to develop a monkeypox rapid point-of-care (POC) test. Chembio is

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

CEMI Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.chembio.com
Security nameChembio Diagnostics Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees337
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Pharmaceutical Preparation Manufacturing

About Chembio Diagnostics Inc.

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.